drugset / Trial / NCT02254148

The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)

NCT02254148

Phase 1 Completed 24 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

To assess the influence of BI 187004 on kinetics of cytochrome P450 (CYP) and P glycoprotein (P-gp) probe drugs as a means of predicting drug-drug interactions.

Timeline

Start
2014-10
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 187004 Small molecule Oral
Subject Caffeine Small molecule Oral
Subject Digoxin Other / unclassified Oral
Subject Metoprolol Other / unclassified Oral
Subject Midazolam Small molecule Oral
Subject Omeprazole Other / unclassified Oral
Subject Warfarin Small molecule Oral

Indications

No indication recorded.